文献速递白血病造血干细胞移植与细胞治疗

中剂量依托泊苷联合环磷酰胺/全身照射方案可改善高危成人急性淋巴细胞白血病异基因移植预后

Improved prognosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults.
PubMed 文献 · Am J Hematol · 2017-11-09

日本移植登记数据库回顾性队列比较成人急性淋巴细胞白血病完全缓解期移植中VP16/CY/TBI(N=376)与CY/TBI(N=1178)方案预后,VP16/CY/TBI显著降低复发(风险比0.75;95%CI 0.56-1.00;P=.05),无白血病生存改善(HR 0.76;95%CI 0.62-0.93;P=.01),非复发死亡未增加(HR 0.88;95%CI 0.65-1.18;P=.38)。

要点

  • VP16/CY/TBI较CY/TBI显著降低复发(风险比0.75;95%CI 0.56-1.00;P=.05)
  • VP16/CY/TBI改善无白血病生存(HR 0.76;95%CI 0.62-0.93;P=.01)
  • 非复发死亡未增加(HR 0.88;95%CI 0.65-1.18;P=.38)

核心结论

  • 中剂量VP16(30-40 mg/kg)加入CY/TBI可显著降低成人高危ALL完全缓解期移植后的复发并改善无白血病生存,且不增加非复发死亡。
  • 作者指出这是首个揭示中剂量VP16加入CY/TBI在高危ALL中疗效的研究。
  • 作者认为需开展大规模前瞻性研究以确立含VP16的新清髓性预处理方案。

研究设计与样本

  • 日本移植登记数据库回顾性队列研究。
  • 比较VP16/CY/TBI(VP16总剂量30-40 mg/kg,N=376)与CY/TBI(N=1178)方案。
  • 对象为2000年1月1日至2014年12月31日期间完全缓解期移植的成人ALL患者。

主要发现

  • VP16/CY/TBI较CY/TBI显著降低复发(风险比0.75;95%CI 0.56-1.00;P=.05)。
  • 无白血病生存改善(HR 0.76;95%CI 0.62-0.93;P=.01)。
  • 在CR1期具有高危因素(微小残留病阳性、不良细胞遗传学或初诊白细胞计数升高)者中HR 0.75(95%CI 0.56-1.00;P=.05)。
  • 在CR2期以后移植者中HR 0.58(95%CI 0.39-0.88;P=.01)。
  • 非复发死亡未增加(HR 0.88;95%CI 0.65-1.18;P=.38),移植后并发症未增加。

关键数值与推荐

  • 中剂量VP16剂量为30-40 mg/kg,加入CY/TBI方案。
  • 复发风险比0.75(95%CI 0.56-1.00;P=.05),VP16/CY/TBI组较CY/TBI组降低。
  • 无白血病生存HR 0.76(95%CI 0.62-0.93;P=.01),VP16/CY/TBI组较CY/TBI组改善。
  • 非复发死亡HR 0.88(95%CI 0.65-1.18;P=.38),两组无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需开展大规模前瞻性研究以确立含VP16的新清髓性预处理方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation (HSCT) with the conventional cyclophosphamide and total body irradiation (CY/TBI) regimen is an essential therapeutic strategy for acute lymphoblastic leukemia (ALL) in adults. Medium-dose etoposide (VP16, 30-40 mg/kg) can be added to intensify this CY/TBI regimen and reduce relapse; however, differences in prognosis between the VP16/CY/TBI and CY/TBI regimens have not yet been fully analyzed. We conducted a retrospective cohort study using a Japanese transplant registry database to compare the prognosis between the VP16/CY/TBI (VP16, total 30-40 mg/kg) (N = 376) and CY/TBI (N = 1178) regimens in adult patients with ALL transplanted at complete remission (CR) between January 1, 2000 and December 31, 2014. Our analyses indicated that VP16/CY/TBI significantly reduced relapse compared with CY/TBI (risk ratio, 0.75; 95% confidence interval [CI], 0.56-1.00; P = .05) with a corresponding improvement in leukemia-free survival (hazard ratio [HR], 0.76; 95%CI, 0.62-0.93; P = .01), particularly in patients transplanted at CR1 with advanced-risk (positive minimal residual disease, presence of poor-risk cytogenetics, or an initial elevated leukocyte count) (HR, 0.75; 95%CI, 0.56-1.00; P = .05) or those transplanted beyond CR2 (HR, 0.58; 95%CI, 0.39-0.88; P = .01). The addition of VP16 did not increase post-transplant complications or nonrelapse mortality (HR, 0.88; 95%CI, 0.65-1.18; P = .38). This study is the first to reveal the efficacy of the addition of medium-dose VP16 to CY/TBI in high-risk ALL. To establish new myeloablative conditioning regimens including VP16, a large-scale prospective study is necessary.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Arai Y, Kondo T, Shigematsu A, et al. Improved prognosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults. Am J Hematol. 2017. PMID: 28983949. doi:10.1002/ajh.24933

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。